Equity / SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
argenx SE American Depositary Shares
XNAS · usd
SIC 3841 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
FIGI BBG00GHB88Y8
825.03▲ 6.40 (0.78%)
As of 2026-10-09
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
818.63
Day's Range
805.07 – 826.78
52-Week Range
661.85 – 1,072.75
Volume
511.0K
Avg Volume
334.2K
Share Statistics
Shares Outstanding
Employees
1,863
Exchange
XNAS
Listed
2017-05-18
Share count as of December 31, 2025
argenx SE American Depositary Shares (ARGX) Financial Statements
View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about argenx SE American Depositary Shares (ARGX)
What is argenx SE American Depositary Shares's Market Cap?
argenx SE American Depositary Shares's Market Cap is $51.1B, based on as-reported figures from SEC (XBRL) filings.
What is argenx SE American Depositary Shares's Trailing P/E?
argenx SE American Depositary Shares's Trailing P/E is 39.5×, based on as-reported figures from SEC (XBRL) filings.
What is argenx SE American Depositary Shares's Net Income (TTM)?
argenx SE American Depositary Shares's Net Income (TTM) is $1.3B, based on as-reported figures from SEC (XBRL) filings.
What is argenx SE American Depositary Shares's Diluted EPS (TTM)?
argenx SE American Depositary Shares's Diluted EPS (TTM) is 20.88, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ARGXAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line Item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Statement of profit or loss and other comprehensive income [abstract]
Product net sales
Other operating income
Total operating income
Cost of sales
Research and development expenses
Selling, general and administrative expenses
Loss from investment in a joint venture
Total operating expenses
Operating profit/(loss)
Financial income
Financial expense
Exchange gains/(losses)
Profit/(Loss) for the year before taxes
Income tax benefit
Profit/(Loss) for the year
Profit/(Loss) for the year attributable to:
Owners of the parent
Basic profit/(loss) per share (in USD per share)
Diluted profit/(loss) per share (in USD per share)